Is It Adverse, Nonadverse, Adaptive, or Artifact?
- PMID: 27770107
- PMCID: PMC5225139
- DOI: 10.1177/0192623316672352
Is It Adverse, Nonadverse, Adaptive, or Artifact?
Abstract
One of the principal challenges facing a toxicologic pathologist is to determine and differentiate a true adverse effect from a nonadverse or an adaptive response. Recent publications from the Society of Toxicologic Pathology (STP) and the European STP provide guidance for determining and communicating adversity in nonclinical toxicology studies. In order to provide a forum to inform and engage in a discussion on this important topic, a continuing education (CE) course was held during the 2016 STP Annual meeting in San Diego, CA. The lectures at this course provided guidance on determining and communicating adversity using case studies involving both clinical pathology and anatomic pathology. In addition, one talk also focused on data quality, study design, and interpretation of artifacts that could hinder the determination of adversity. The CE course ended with a talk on understanding adversity in preclinical studies and engaging the regulatory agencies in the decision-making process. This manuscript is designed to provide brief summaries of all the talks in this well-received CE course.
Keywords: adaptive response; adversity; artifact; nonadverse response.
Similar articles
-
Toxicologic Pathology Forum*: Commentary on "Opinion on Designation of Adverse and Nonadverse Histopathological Findings in Toxicity Studies: The Pathologist's Dilemma".Toxicol Pathol. 2019 Jul;47(5):574-576. doi: 10.1177/0192623319840355. Epub 2019 Jul 14. Toxicol Pathol. 2019. PMID: 31303126
-
Scientific and Regulatory Policy Committee Points to Consider*: Review of Scientific and Regulatory Policy Committee Points to Consider: Review of Current Practices for Ultrastructural Pathology Evaluations in Support of Nonclinical Toxicology Studies.Toxicol Pathol. 2019 Jun;47(4):461-468. doi: 10.1177/0192623319835170. Epub 2019 Apr 24. Toxicol Pathol. 2019. PMID: 31018785
-
Society of Toxicologic Pathology position paper on best practices on recovery studies: the role of the anatomic pathologist.Toxicol Pathol. 2013;41(8):1159-69. doi: 10.1177/0192623313481513. Epub 2013 Mar 26. Toxicol Pathol. 2013. PMID: 23531793 Review.
-
Toxicologic Pathology Forum*: Opinion on Designation of Adverse and Nonadverse Histopathological Findings in Toxicity Studies: The Pathologist's Dilemma.Toxicol Pathol. 2019 Jul;47(5):564-573. doi: 10.1177/0192623319854040. Epub 2019 Jul 10. Toxicol Pathol. 2019. PMID: 31291835
-
Principles for Assessing Adversity in Toxicologic Clinical Pathology.Toxicol Pathol. 2017 Feb;45(2):260-266. doi: 10.1177/0192623316681646. Epub 2017 Jan 5. Toxicol Pathol. 2017. PMID: 28056663 Review.
Cited by
-
Safety of Elixinol Hemp Extract: In Vitro Genetic Toxicity and Subchronic Toxicity in Rats.J Toxicol. 2023 Dec 11;2023:5982883. doi: 10.1155/2023/5982883. eCollection 2023. J Toxicol. 2023. PMID: 38111631 Free PMC article.
-
Safety and efficacy of sFilm-FS, a novel biodegradable fibrin sealant, in Göttingen minipigs.J Toxicol Pathol. 2021 Oct;34(4):319-330. doi: 10.1293/tox.2021-0030. Epub 2021 Jul 10. J Toxicol Pathol. 2021. PMID: 34629733 Free PMC article.
-
Toxicity of humidifier disinfectant polyhexamethylene guanidine hydrochloride by two-week whole body-inhalation exposure in rats.J Toxicol Pathol. 2020 Oct;33(4):265-277. doi: 10.1293/tox.2020-0043. Epub 2020 Aug 9. J Toxicol Pathol. 2020. PMID: 33239844 Free PMC article.
-
Safety evaluation of 2'-deoxy-2'-fluoro nucleotides in GalNAc-siRNA conjugates.Nucleic Acids Res. 2019 Apr 23;47(7):3306-3320. doi: 10.1093/nar/gkz140. Nucleic Acids Res. 2019. PMID: 30820542 Free PMC article.
-
Proposing new approaches for the risk characterisation of single chemicals and chemical mixtures: The source related Hazard Quotient (HQS) and Hazard Index (HIS) and the adversity specific Hazard Index (HIA).Toxicol Rep. 2019 Jun 21;6:632-636. doi: 10.1016/j.toxrep.2019.06.010. eCollection 2019. Toxicol Rep. 2019. PMID: 31334033 Free PMC article.
References
-
- Barone S, Jr, Moser VC. The effects of perinatal tebuconazole exposure on adult neurological, immunological, and reproductive function in rats. Toxicol Sci. 2004;77:183. - PubMed
-
- Calabrese EJ, Baldwin LA. Improved method for selection of the NOAEL. Regul Toxicol Pharmacol. 1994;19:48–50. - PubMed
-
- Cavagnaro JA, Beilke LD. What the AEL is the NOAEL?. American College of Toxicology, 35th Annual Meeting; Orlando, FL. 2014.
-
- CDER. Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers, 40CFR Part 261. US Government Printing Office; Washington, DC: 2005.
-
- Clemo FA, Evering WE, Snyder PW, Albassam MA. Differentiating spontaneous from drug-induced vascular injury in the dog. Toxicol Pathol. 2003;31 suppl:25–31. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical